Afatinib in advanced squamous cell carcinoma of the lung: Added benefit not proven

Considering Afatinib in advanced squamous cell carcinoma of the lung, neither the direct nor the indirect comparison conducted by the drug manufacturer allows conclusions on advantages or disadvantages in comparison with the appropriate comparator therapy.